2026 Bayer AG Highlights: Kerendia Japan Launch, REVEAL Cardiac Trial Success & $7.25B Roundup Settlement

Bayer AG – Key Developments in August 2026

Bayer AG, listed on Xetra and trading at EUR 48.67 as of 27 August 2026, reported several developments that may influence its financial outlook and market perception.

1. Clinical Advancement – Phase III REVEAL Study

• Date of disclosure: 30 August 2026
• Source: www.finanznachrichten.de
• Content: Bayer presented results from the Phase III REVEAL study, which evaluated the investigational PET radiotracer Iodine‑124 Evuzamitide in patients suspected of cardiac amyloidosis. The study was presented as a late‑breaker at the 2026 European Society of Cardiology (ESC) Congress.
• Implication: Positive outcomes could support further regulatory approval of the radiotracer for imaging cardiac amyloidosis, potentially expanding Bayer’s portfolio in cardiovascular diagnostics.

2. Expansion of Kerendia in Japan

• Date of disclosure: 28 August 2026 (multiple sources)
• Sources: www.boersennews.de , www.index-radar.de , www.finanznachrichten.de
• Content: Bayer applied for and received approval of Kerendia for non‑diabetic chronic kidney disease (CKD) in Japan. The drug, already approved in other markets, is expected to become a “potential blockbuster” in the Japanese market.
• Market Impact: The approval is viewed as a significant growth driver, particularly given Japan’s large CKD patient population. Analysts note that the approval could enhance Bayer’s global standing in the nephrology segment and contribute to revenue diversification.

3. Legal Resolution – Roundup Settlement

• Date of disclosure: 28 August 2026 (multiple sources)
• Sources: www.avanza.se , www.handelsblatt.com , www.manager-magazin.de , www.finanznachrichten.de
• Content: A U.S. appellate court rejected an appeal against Bayer’s planned USD 7.25 billion settlement related to Roundup litigation. The settlement resolves ongoing claims linked to glyphosate exposure.
• Financial Consequence: The settlement confirms a significant liability for Bayer, potentially impacting earnings and cash flow projections for the upcoming fiscal year. The resolution, however, removes ongoing litigation uncertainty.

4. Ancillary Developments

• Telecommunications Upgrade at FC Bayer 04 Leverkusen (29 August 2026, www.teltarif.de ) – While primarily a stadium modernization project, the partnership underscores Bayer’s continued investment in its football club and community engagement.
• Phase III Study and Kerendia Approval are the principal items directly influencing Bayer’s financial and strategic trajectory for the remainder of 2026.

Key Takeaways

These developments collectively shape Bayer AG’s risk profile and growth prospects, with the Japanese Kerendia approval representing a notable opportunity against the backdrop of the Roundup settlement’s financial impact.